Why Alkermes PLC Shares Temporarily Spiked Higher

Alkermes presents top-line results from a late-stage schizophrenia study before the opening bell. Can its shares head even higher?

Apr 8, 2014 at 1:02PM


What: Shares of Alkermes (NASDAQ:ALKS), a global biopharmaceutical company developing therapies to treat a range of diseases and disorders, jumped as much as 11% after reporting positive top-line results from a late-stage study involving experimental intramuscular injection aripiprazole lauroxil for the treatment of schizophrenia. Shares have since cooled and are up less than 4% as of this writing.

So what: According to Alkermes' press release, patients taking the once-monthly treatment, either in a 441 mg or 882 mg dose, "demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12 compared to placebo." On top of meeting its primary endpoint, aripiprazole lauroxil also met its secondary endpoint of improvement from baseline in the Clinical Global Impression – Improvement Scale at week 12. Following this data, Alkermes is merely dotting its I's and crossing its T's in preparation for a new drug application filing next quarter. The press release also notes that the company will release its full phase 3 data on the drug at an upcoming medical conference.

Now what: It's always a bit tough to get too excited when you don't have the full data set in front of you, but as far as this is set to become an additional long-term injectable dosing option for schizophrenia patients this looks like a winner. The therapy was well-tolerated, safe, and it met both its primary and secondary endpoint, so I'm certainly leaning toward it having a better chance of being approved than rejected by the Food and Drug Administration at this point in time.

Alkermes itself is a really interesting case wherein a number of mid-cap and larger biopharmaceutical companies are moving their pipeline focus onto rare diseases, it's pushing back into the large chronic disease market. The company is profitable and it has a healthy and growing portfolio and pipeline. Long story short, I won't beat around the bush about recommending you get Alkermes on your watchlist and would suggest biotech-savvy investors dive more deeply into this company when they have the chance.

Alkermes may have popped today, but it'll likely be hard-pressed to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information